715 related articles for article (PubMed ID: 26620208)
1. Anti-angiogenic alternatives to VEGF blockade.
Khan KA; Bicknell R
Clin Exp Metastasis; 2016 Feb; 33(2):197-210. PubMed ID: 26620208
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
3. Anti-Angiogenics: Current Situation and Future Perspectives.
Zirlik K; Duyster J
Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor: biology and therapeutic applications.
Ho QT; Kuo CJ
Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
8. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
9. Tumor angiogenesis and anti-angiogenic therapy.
Kubota Y
Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
[TBL] [Abstract][Full Text] [Related]
10. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
11. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis and angiogenesis inhibitors in cancer.
Giavazzi R; Taraboletti G
Forum (Genova); 1999; 9(3):261-72. PubMed ID: 10504172
[TBL] [Abstract][Full Text] [Related]
13. Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.
Siveen KS; Prabhu K; Krishnankutty R; Kuttikrishnan S; Tsakou M; Alali FQ; Dermime S; Mohammad RM; Uddin S
Curr Vasc Pharmacol; 2017; 15(4):339-351. PubMed ID: 28056756
[TBL] [Abstract][Full Text] [Related]
14. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) inhibition--a critical review.
Moreira IS; Fernandes PA; Ramos MJ
Anticancer Agents Med Chem; 2007 Mar; 7(2):223-45. PubMed ID: 17348829
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
17. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Lindsay CR; MacPherson IR; Cassidy J
Future Oncol; 2009 May; 5(4):421-32. PubMed ID: 19450171
[TBL] [Abstract][Full Text] [Related]
18. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
Jászai J; Schmidt MHH
Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
[TBL] [Abstract][Full Text] [Related]
19. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
Niu G; Chen X
Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
